Sangamo BioSciences

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. We are worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence. Our primary mission is to develop ZFP Therapeutics®. We have ongoing clinical programs to evaluate ZFP TFs and ZFNs as novel approaches to unmet medical needs where we believe we have a differential technical advantage to impact the outcome of disease by functioning at the DNA level.
Company Growth (employees)
Type
Public
HQ
Richmond, US
Founded
1995
Size (employees)
131 (est)+11%
Sangamo BioSciences was founded in 1995 and is headquartered in Richmond, US

Key People at Sangamo BioSciences

Edward Lanphier

Edward Lanphier

President and CEO

Sangamo BioSciences Office Locations

Sangamo BioSciences has an office in Richmond
Richmond, US (HQ)
501 Canal Blvd

Sangamo BioSciences Data and Metrics

Sangamo BioSciences Financial Metrics

Sangamo BioSciences's revenue was reported to be $19.4 m in FY, 2016
Numbers are in $, USD

Revenue (FY, 2016)

19.4 m

Revenue growth (FY, 2015 - FY, 2016), %

(51%)

Net income (FY, 2016)

(71.7 m)

EBIT (FY, 2016)

(72.6 m)

Market capitalization (26-May-2017)

521.6 m

Closing share price (26-May-2017)

7.8

Cash (31-Dec-2016)

22.1 m
Sangamo BioSciences's current market capitalization is $521.6 m.
Numbers are in $, USDFY, 2013Y, 2014Y, 2015FY, 2016

Revenue

24.1 m45.9 m39.5 m19.4 m

Revenue growth, %

90%(14%)(51%)

Operating expense total

50.8 m72.7 m86.4 m91.9 m

EBIT

(26.7 m)(26.8 m)(46.9 m)(72.6 m)

EBIT margin, %

(111%)(58%)(119%)(374%)

Net Income

(26.6 m)(26.4 m)(40.7 m)(71.7 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

10.2 m6 m69.5 m22.1 m

Accounts Receivable

3.2 m10.4 m2.5 m5 m

Inventories

Current Assets

97.3 m190.9 m212.6 m149.6 m

PP&E

1.4 m1.5 m2.9 m6.6 m

Goodwill

1.6 m1.6 m1.6 m1.6 m

Total Assets

140.8 m243.2 m217.2 m157.9 m

Accounts Payable

Current Liabilities

10.1 m20.9 m20.1 m13.3 m

Additional Paid-in Capital

423.2 m534.5 m561 m576.4 m

Retained Earnings

(302.1 m)(328.6 m)(369.3 m)(440.9 m)

Total Equity

121.7 m206.6 m192.4 m136.2 m

Financial Leverage

1.2 x1.2 x1.1 x1.2 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(26.6 m)(26.4 m)(40.7 m)(71.7 m)

Depreciation and Amortization

569 k549 k988 k997 k

Accounts Receivable

1 m(7.2 m)7.8 m(2.1 m)

Inventories

Accounts Payable

Cash From Operating Activities

(19.5 m)(5.7 m)(33.7 m)(65.9 m)

Purchases of PP&E

(432 k)(621 k)(2.4 m)(732 k)

Cash From Financing Activities

76.1 m102.2 m19.7 m337 k
Y, 2016

Financial Leverage

1.2 x

Sangamo BioSciences Market Value History

Sangamo BioSciences Company Life and Culture

You may also be interested in